Facultad
Jaclyn Bosco, PhD, MPH, FISPE
Vice President, Global Head of Epidemiology & Database Studies, IQVIA, United States
Dr. Jaclyn Bosco Global Head of Epidemiology in Real World Solutions at IQVIA, is responsible for driving real-world evidence (RWE) generation for regulators, clinicians, patients and payers using passive and primary data collection through clinicians and person-generated health to support the safety and effectiveness of drugs, biologics, and medical devices from early clinical development through the post-approval phase. She identifies the best approach for capturing data on a global scale as well applies local approaches to address market-specific needs. As a thought leader in real world research, she is invited to speak at international congresses and sits on scientific advisory boards and committees.
Linda Kalilani, PhD, MSc
Senior Director and Head of Oncology Epidemiology, GlaxoSmithKline, United States
Linda Kalilani is Senior Director & Head of Oncology Epidemiology at GlaxoSmithKline. She has worked as an epidemiologist in the pharmaceutical industry for over 10 years. She has led the development of cross-functional real-world evidence strategies, has extensive experience leading the design and execution of real-world evidence studies, and leading initiatives to improve governance processes for implementing real world evidence studies. Linda holds a PhD in Epidemiology from the University of North Carolina at Chapel Hill, a Masters’ Degree in Epidemiology from University of Cambridge, UK and a Medical Degree from the University of Malawi.
Rachel Sobel, DrPH, FISPE
Vice President, Head of Pharmacoepidemiology, Regeneron Pharmaceuticals Inc., United States
Dr. Sobel has over 24 years of experience in epidemiology, risk management, and registries. She is currently Head of Pharmacoepidemiology at Regeneron in Global Patient Safety and has held roles of increasing responsibility at Pfizer Inc and UBC, a CRO. She has extensive experience in the use of RWE for regulatory decision making and using epidemiology to support multiple aspects of drug safety, such as post-authorization safety studies and Risk Evaluation and Mitigation Strategy (REMS) for FDA, EMA, and others. Her work has been published in multiple peer review journals, and she is also an active member of the International Society of Pharmacoepidemiology (ISPE), where she has held a number of leadership positions.
Montse Soriano Gabarro, MD, MSc, FISPE
Head Partnerships and Integrated Evidence Generation Office, Bayer AG, Germany
Montse Soriano Gabarro, MD, MSc, FISPE, is a physician and epidemiologist with > 25 years of experience in public health, epidemiological and pharmacoepidemiological research. She initiated her career at the University Barcelona, followed by several years of field and epidemiological work at the CDC, Atlanta, US. In 2005 Montse joined GSK Biologicals leading the WW Epidemiology Biologicals team. Since 2010 she works at Bayer AG where she led Epidemiology team until 2020. She is currently Head of Partnerships, Policy and the Integrated Evidence Generation Office at Bayer AG. Montse is a Bayer Science Distinguished Fellow, as a Fellow of the International Society for Pharmacoepidemiology (ISPE).
¿Tiene una cuenta?